BCRX - BioCryst Pharmaceuticals

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by StockJock-e, Dec 19, 2016.

  1. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, an oral serine protease inhibitor, which is in Phase II clinical trial for HAE; and other second generation HAE compounds, an oral serine protease inhibitor, which is in preclinical stage. The company's product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in preparation to file for regulatory approval. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; and Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

    [​IMG]
     
  2. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    Upgrade from JMP Securities with a $10 target last week.
     
  3. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,204
    Likes Received:
    3,026
    Down 23% pre-market. Announced positive results on phase 2 trial, not sure why it's down

    upload_2017-2-27_7-57-5.png

    BioCryst Pharma (BCRX) Announces Positive Interim Results from its APeX-1 Trial
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced results from an interim analysis of its Phase 2 APeX-1 trial in hereditary angioedema (HAE). APeX-1 is a dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients.

    Read full article here: http://www.streetinsider.com/Corpor...m+Results+from+its+APeX-1+Trial/12595042.html
     
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    Rough day for longs, but $4 support?
     
  5. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,204
    Likes Received:
    3,026
    Good day for any longs who got in today ;) Wish I would have acted on my last post saying positive news, but stock way down...

     
  6. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    BioCryst Pharmaceuticals ($BCRX) is likely to see early strength after announcing that Mundipharma has obtained regulatory approval of Mundesinefor the treatment of relapsed/refractory PTCL by the Ministry of Health, Labor and Welfare in Japan.
     
  7. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    Biotech runner of the day! +40%
     
  8. Ciao (Sheppy)

    Ciao (Sheppy) Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    4,002
    Likes Received:
    617
    shares of BioCryst Pharmaceuticals (BCRX) rose 19.1% to $6.11. The Research Triangle Park, N.C.-based firm on Thursday announced additional positive results from a second interim analysis of a phase two study of BCX7353 as a preventative treatment to reduce the frequency of attacks in patients with hereditary angioedema.
     
  9. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    Lets see if this can hold above $7 today
     
  10. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,272
    Likes Received:
    515
  11. Syynik

    Syynik Well-Known Member

    Joined:
    Aug 7, 2016
    Messages:
    511
    Likes Received:
    274
    This is being pumped(?) as a Covid play. I've got it on watch, great volume so far.
     
  12. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,968
    Likes Received:
    3,208
    Testing that Nov down gap it had
     

Share This Page